Argent Biopharma (AU:RGT)
ASX:RGT
RGT Stock Chart & Stats
AU$0.08
>-AU$0.01(-2.00%)
At close: 4:00 PM EST
AU$0.08
>-AU$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.32
Previous CloseN/A
Volume362.25K
Average Volume (3M)77.74K
Market Cap
AU$3.39M
Enterprise ValueAU$10.30M
Total Cash (Recent Filing)AU$1.02M
Total Debt (Recent Filing)AU$8.29M
Price to Earnings (P/E)―
Beta-0.77
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding89,192,314
10 Day Avg. Volume131,422
30 Day Avg. Volume77,736
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginA material gross margin improvement in 2025 indicates stronger unit economics or a higher-margin product mix. If sustained, higher gross margins provide a structural lever to restore profitability once fixed operating costs are controlled or revenue stabilizes, improving long-term earnings power.
Prior Positive EquityHaving reported positive stockholders' equity as recently as 2022 shows the company previously achieved a more stable capital structure. That history implies prior access to capital or operational scale and suggests management and stakeholders have levers to repair the balance sheet through financing or restructuring if execution improves.
Industry ExposureOperating in specialty and generic pharmaceuticals gives durable structural support: recurring demand, regulatory barriers, and clinical/product differentiation can sustain long-term revenue streams. If the company stabilizes operations, industry dynamics favorable to margin recovery and pricing durability remain relevant.
Bears Say
Negative EquitySustained negative equity is a deep structural weakness that limits financial flexibility, raises insolvency risk, and hampers ability to raise non-dilutive capital. It constrains strategic options, increases creditor scrutiny, and makes long-term R&D or commercialization investments harder without decisive balance-sheet repair.
Sharp Revenue DeclineA multi-year, steep revenue contraction destroys scale economics and weakens competitive position. Loss of top-line momentum makes fixed costs harder to cover, reduces bargaining power with partners, and materially raises the bar for returning to sustainable profitability without clear market-share or product strategy reversal.
Persistent Cash BurnConsistently large negative free cash flow and zero operating cash flow indicate ongoing reliance on external funding. This structural cash burn reduces runway, forces dilutive financing or higher debt, and elevates execution risk over the medium term unless the company substantively reduces outflows or secures durable funding sources.
Argent Biopharma News
RGT FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest share price was AU$0.03 and its highest was AU$0.32 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is AU$3.39M.
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Aug 27, 2026 which is in 141 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Feb 27, 2026. The company reported -AU$0.038 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.038.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 89,192,314 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -AU$0.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in AU:RGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:RGT Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.17%
12-Months-Change
Fundamentals
Return on Equity
258.94%
Trailing 12-Months
Asset Growth
-29.21%
Trailing 12-Months
Company Description
Argent Biopharma
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―